Yahoo Web Search

Search results

1. • UChicago joins multisite study to improve health o | Newswise

     Newswise· 2 days ago

     The University of Chicago is among five clinical sites conducting a first-of-its-kind study aimed at uncovering risk factors and targeted interventions to better prevent disease ...

2. • Small Business - Salisbury Post | Salisbury Post

     The Salisbury Post· 2 days ago

     SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and

3. • 

     Cannabis use common among patients, with most usin | Newswise

     Newswise· 3 days ago

     One in six patients in primary care reported cannabis use, with 35% of those using at levels...

4. • 

     Creativity Not Influenced by Maternal Epilepsy

     MedPage Today· 4 days ago

     Prenatal exposure to high doses of anti-seizure drugs may influence executive function, however

5. • BriaCell Presents Clinical Efficacy Data at ASCO 2024

     Digital Journal· 4 days ago

     BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literatureBria-IMT™ PFS compares favorably to PFS of most recent treatment in 48% of Antibody-Drug ...

6. • PSC Partners Announces the First Patient Enrolled Into the WIND-PSC Study, a Global Prospective...

     Benzinga· 3 days ago

     PSC Partners and PSC Partners Canada, both patient-led non-profit organizations supporting education and research in primary sclerosing cholangitis (PSC), announced today the enrollment of the ...

7. • Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in...

     Benzinga· 5 days ago

     SUZHOU, China, and ROCKVILLE, Md., June 1, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related

8. • Small Business - Picayune Item | Picayune Item

     The Picayune Item· 3 days ago

     UNION therapeutics announces successful completion of the ADESOS Phase 2b study and presentation of data at the RAVE Conference 2024 PR Newswire HELLERUP, Denmark, June 4, 2024 ADESOS Phase 2b study evaluating orismilast as an oral treatment in

9. • 

     HPV Testing Outperforms Pap Smear for Detecting Cervical Cancer Precursor Lesions

     MedPage Today· 7 days ago

     The risk of CIN3+ was also lower 8 years after HPV testing as compared with 3 years after negative...

10. • Transgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead...

      Benzinga· 4 days ago

      Strasbourg, France, June 3, 2024, 7:30 a.m. CET – Transgene TNG, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer today announces that the ...